Esther Priel
Founder, CEO & CSO
Your CSV is on the way
We’ve sent your CSV file to email@email.com
Claimed by
owner Add to list
Neuromagen Pharma
Former names:
Novel Drugs for Neurodegenerative Diseases
Stealth Mode
Neuromagen Pharma
Neuromagen Pharma Overview
Neuromagen Pharma is a pharmaceutical company developing a new class of innovative small molecules that activate telomerase reverse transcriptase (TERT), an enzyme that plays a major role in preventing cellular senescence.
The companys mission is to develop drugs to delay the onset and the progression of neurodegenerative diseases such as ALS and to improve and extend patients lives.
Neuromagen Pharma received FDA Orphan Drug Designation for its AGS-499 Drug Candidate to Slow the Progression of ALS (Amyotrophic Lateral Sclerosis).
The companys mission is to develop drugs to delay the onset and the progression of neurodegenerative diseases such as ALS and to improve and extend patients lives.
Neuromagen Pharma received FDA Orphan Drug Designation for its AGS-499 Drug Candidate to Slow the Progression of ALS (Amyotrophic Lateral Sclerosis).
Cumulative Funding Raised Over Time ($)
Employees Over Time
Neuromagen Pharma Climate Tech relevance
null
No Data, yet.
Sorry, no content found under this section.
Jun 23, 2022
www.prnewswire.com
Neuromagen Pharma Announces the Appointment of Professor Gal Ifergane, Head of the Neurology Department at Soroka Medical Center, to its Scientific Advisory Board
#Partners #Management Changes
May 5, 2022
www.biospace.com
Neuromagen Pharma Ltd. Receives FDA Orphan Drug Designation for its AGS-499 Drug Candidate to Slow the Progression of ALS (Amyotrophic Lateral Sclerosis) | BioSpace
#Customers #Partners
Mar 21, 2022
www.prnewswire.com
Neuromagen Pharma Announces the Approval of a NIS 1.8M Budget from the Israel Innovation Authority R&D Fund Incentive Program
#Investment
Feb 8, 2022
www.prnewswire.com
Neuromagen Pharma to Present at the BIO-Europe Spring 2022 Conference
#Partners #Expand
Nov 2, 2021
www-timesofisrael-com.cdn.ampproject.org
Israeli drug that slowed Alzheimer's, ALS in mice gets funding to start trials
#Investment
Companies you might be interested in
Driven by Finder AI
-
Lutris PharmaAnticancer Therapy for Patients Treated with EGFR Inhibitors1-10 employees • Funding Stage: Seed
shared sectors
Also shared
Are these companies similar? -
Stem Cell MedicineStem Cell Therapeutic Technology11-50 employees • Funding Stage: Seed
shared sectors
Also shared
Are these companies similar? -
TenAces BiosciencesMolecular Glue Therapeutics1-10 employees • Funding Stage: Seed
shared sectors
Also shared
Are these companies similar? -
DenovAI BiotechDynamic Protein Design11-50 employees • Funding Stage: Seed
shared sectors
Also shared
Are these companies similar?
Primary sector
Total funding
Funding stage
Number of employees
Founded
Related Content
Lists. Maps. Reports
Team Members
EP
DB
HG
Contact Team
Affiliated Organizations
(null)Web & social links
https://www.neuromagen.com/
Locations
Israel
HaEnergia Street 77, Be'er Sheva, Israel
Offices Abroad
Photos & videos
(1)No Data, yet.
Sorry, no content found under this section.
Neuromagen Pharma Business
Sector
Primary:
Health Tech & Life Sciences
Target Customer
Core Technology
Use Cases
(0)Tech Community Involvement
(0)Neuromagen Pharma Financials
Cumulative Funding Raised Over Time ($)
No Data, yet.
Sorry, no content found under this section.
Public Offerings & Exits
Private Equity Funding
Seed
$2M
Nov 2021
0
Investors
$2M
Non-Equity Funding
Mergers and Acquisitions
Neuromagen Pharma Lifecycle
Cumulative Funding Raised Over Time ($)
Timeline
Employees Over Time
News Over Time
No Data, yet.
Sorry, no content found under this section.
Neuromagen Pharma News
News Over Time
No Data, yet.
Sorry, no content found under this section.
News Articles
Jun 23, 2022
www.prnewswire.com
Neuromagen Pharma Announces the Appointment of Professor Gal Ifergane, Head of the Neurology Department at Soroka Medical Center, to its Scientific Advisory Board
#Partners #Management Changes
May 5, 2022
www.biospace.com
Neuromagen Pharma Ltd. Receives FDA Orphan Drug Designation for its AGS-499 Drug Candidate to Slow the Progression of ALS (Amyotrophic Lateral Sclerosis) | BioSpace
#Customers #Partners
Mar 21, 2022
www.prnewswire.com
Neuromagen Pharma Announces the Approval of a NIS 1.8M Budget from the Israel Innovation Authority R&D Fund Incentive Program
#Investment
Feb 8, 2022
www.prnewswire.com
Neuromagen Pharma to Present at the BIO-Europe Spring 2022 Conference
#Partners #Expand
Nov 2, 2021
www-timesofisrael-com.cdn.ampproject.org
Israeli drug that slowed Alzheimer's, ALS in mice gets funding to start trials
#Investment
Related Content
Neuromagen Pharma Team
No Data, yet.
Sorry, no content found under this section.
Employees Over Time
Companies you might be interested in
Driven by Finder AI
-
Lutris PharmaAnticancer Therapy for Patients Treated with EGFR Inhibitors1-10 employees • Funding Stage: Seed
shared sectors
Also shared
Are these companies similar? -
Stem Cell MedicineStem Cell Therapeutic Technology11-50 employees • Funding Stage: Seed
shared sectors
Also shared
Are these companies similar? -
TenAces BiosciencesMolecular Glue Therapeutics1-10 employees • Funding Stage: Seed
shared sectors
Also shared
Are these companies similar? -
DenovAI BiotechDynamic Protein Design11-50 employees • Funding Stage: Seed
shared sectors
Also shared
Are these companies similar?
Neuromagen Pharma Internal
Create note
Notes
(undefined)
Filter notes
Content Writer
undefined
BI Verification
undefined
Phone Number
undefined
Israel Register ID
undefined
Confidence Score
undefined
Missing Fields
undefined
Profile Creator
undefined
Profile Update
undefined
undefined
Access Comprehensive Financial Analytics
Create a free account to:
- Explore detailed financial analytics.
- Track company growth and size.
- Connect with company team members.
I already have access,
I already have access,